GLP-1 medications such as Ozempic and Mounjaro are gaining attention for their impacts on diabetes and weight loss, but questions remain about long-term sustainability. A recent study involving nearly 700 participants indicated encouraging results: average weight losses of 9.2%, 20.2%, and 30.8% depending on tirzepatide dosages, with participants reaching their lowest weights in around 22 months. Despite noting that the study has not been peer-reviewed, experts remain hopeful about the sustained effects of these drugs on weight management and health outcomes.
According to a new study, people taking Mounjaro have some cause for relief regarding the long-term sustainability of weight loss.
Participants in the study lost, on average, 9.2%, 20.2%, and 30.8% of their body weight depending on the dosage of tirzepatide.
Collection
[
|
...
]